Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Poorer virologic response to nevirapine vs efavirenz-based antiretroviral therapy (ART) has been reported in adult systematic reviews and pediatric studies. METHODS: We compared drug discontinuation and viral load (VL) response in ART-naïve Ugandan/Zimbabwean children ≥3 years of age initiating ART with clinician-chosen nevirapine vs efavirenz in the ARROW trial. Predictors of suppression <80, <400 and <1000 copies/ml at 36, 48 and 144 weeks were identified using multivariable logistic regression with backwards elimination (p=0.1). RESULTS: 445(53%) children received efavirenz and 391(47%) nevirapine. Children receiving efavirenz were older (median 8.6 years vs 7.5 nevirapine, p<0.001) and had higher CD4% (12% vs 10%, p=0.05) but similar pre-ART VL (p=0.17). The initial non-nucleoside-reverse-transcriptase-inhibitor (NNRTI) was permanently discontinued for adverse events in 7/445 (2%) children initiating efavirenz vs 9/391 (2%) initiating nevirapine (p=0.46); at switch to second-line in 17 vs 23, for tuberculosis in 0 vs 26, for pregnancy in 6 vs 0, and for other reasons in 15 vs 5. Early (36-48 week) virologic suppression <80 copies/ml was superior with efavirenz, particularly in children with higher pre-ART VL (p=0.0004); longer-term suppression was superior with nevirapine in older children (p=0.05). Early suppression was poorer in the youngest and oldest children, regardless of NNRTI (p=0.02); longer-term suppression was poorer in those with higher pre-ART VL regardless of NNRTI (p=0.05). Results were broadly similar for <400 and <1000 copies/ml. CONCLUSION: Short-term VL suppression favored efavirenz, but long-term relative performance was age-dependent, with better suppression in older children with nevirapine, supporting WHO's recommendation that nevirapine remain an alternative NNRTI.

Original publication

DOI

10.1097/INF.0000000000001505

Type

Journal article

Journal

Pediatr Infect Dis J

Publication Date

23/12/2016